key: cord-1046225-zldzstyh
authors: Huygens, S.; Oude Munnink, B.; Gharbharan, A.; Koopmans, M.; Rijnders, B.
title: High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
date: 2022-04-06
journal: nan
DOI: 10.1101/2022.04.06.22273503
sha: 9d076db549600bb34fdb28f023e90af890d9c013
doc_id: 1046225
cord_uid: zldzstyh

Background: Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain. It retains activity against the Omicron BA.1 variant and is used to treat immunocompromised patients as they are at increased risk for a severe outcome of COVID-19. Methods: We studied viral evolution in 47 immunocompromised patients infected with Omicron BA.1 or 2 and treated with sotrovimab. SARS-CoV-2 PCR was performed at baseline and weekly thereafter until Ct-value was [≥] 30. All RNA samples were sequenced to determine the variant and occurrence of mutations, in particular in the Spike protein, after treatment. Results: Twenty-four (51%) of the 47 patients were male and their median age was 63 years. Thirty-one (66%) had undergone a solid organ transplantation and 13 (28%) had received prior B-cell depleting therapy. Despite a history of vaccination, 24 of 30 patients with available data on anti-SARS-CoV-2 IgG Spike antibodies prior to treatment with sotrovimab had very low or no antibodies. Median time to viral clearance (Ct-value [≥] 30) after treatment was 15 days (IQR 7-22). However, viral RNA with low Ct-values was continuously detected for at least 28 days after treatment in four patients infected with BA.1. Mutations in the Spike protein at position 337 or 340 were observed in all four patients. Similar mutations were also found after treatment of two patients with a BA.2 infection but both cleared the virus within two weeks. Thus following treatment with sotrovimab, spike mutations associated with reduced in vitro susceptibility were detected in 6 of 47 (13%) patients. Conclusion: Viral evolution towards resistance against sotrovimab can explain treatment failure in most immunocompromised patients and these patients can remain infectious after treatment. Therefore, documenting viral clearance after treatment is recommended to avoid that these patients unintentionally become a source of new, sotrovimab resistant, variants. Research on direct acting antivirals and possibly combination therapy for the treatment of COVID-19 in immunocompromised patients is needed.

Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain. It retains activity against the Omicron BA.1 variant and is used to treat immunocompromised patients as they are at increased risk for a severe outcome of COVID-19.

We studied viral evolution in 47 immunocompromised patients infected with Omicron BA.1 or 2 and treated with sotrovimab. SARS-CoV-2 PCR was performed at baseline and weekly thereafter until Ctvalue was ≥ 30. All RNA samples were sequenced to determine the variant and occurrence of mutations, in particular in the Spike protein, after treatment.

Twenty-four (51%) of the 47 patients were male and their median age was 63 years. Thirty-one (66%) had undergone a solid organ transplantation and 13 (28%) had received prior B-cell depleting therapy.

Despite a history of vaccination, 24 of 30 patients with available data on anti-SARS-CoV-2 IgG Spike antibodies prior to treatment with sotrovimab had very low or no antibodies. Median time to viral clearance (Ct-value ≥ 30) after treatment was 15 days (IQR 7-22). However, viral RNA with low Ct-values was continuously detected for at least 28 days after treatment in four patients infected with BA.1.

Mutations in the Spike protein at position 337 or 340 were observed in all four patients. Similar mutations were also found after treatment of two patients with a BA.2 infection but both cleared the virus within two weeks. Thus following treatment with sotrovimab, spike mutations associated with reduced in vitro susceptibility were detected in 6 of 47 (13%) patients.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.06.22273503 doi: medRxiv preprint immunocompromised patients and these patients can remain infectious after treatment. Therefore, documenting viral clearance after treatment is recommended to avoid that these patients unintentionally become a source of new, sotrovimab resistant, variants. Research on direct acting antivirals and possibly combination therapy for the treatment of COVID-19 in immunocompromised patients is needed.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022.

Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain of sarbecoviruses. It is one of the few approved monoclonals that retains activity against the Omicron BA.1 variant of concern (VOC). 1 Immunocompromised patients are at increased risk for a severe outcome of COVID-19 even after full vaccination against SARS-CoV-2. Indeed, the vaccination response is often reduced and can be completely absent in patients with combined T-cell and B-cell dysfunction. 2,3 Furthermore, prolonged viral replication and evolution has been described in the immunocompromised host. 4, 5 Given the risk for a poor outcome, monoclonal antibody-based therapy is used to treat these patients. Especially during antibody monotherapy, viral evolution towards resistance against the antibody can be expected when replication is not sufficiently contained. Recently, the selection of mutations in the spike protein of the Delta VOC in 4 of 100 patients treated with sotrovimab was reported and all 4 were immunocompromised. 6 Specifically, mutations at position 337 and 340 known to reduce susceptibility to sotrovimab were found. 7 We studied viral evolution in 47 immunocompromised patients treated with sotrovimab for an infection with the Omicron VOC.

At Erasmus University Medical Center in Rotterdam, sotrovimab became available on January26 th ,2022. It is used to treat immunocompromised patients infected with the SARS-CoV-2 Omicron VOC in the outpatient and inpatient setting. A SARS-CoV-2 PCR was performed at baseline and weekly thereafter, also after discharge until the PCR Ct-value was ≥30. 8 Baseline and follow-up samples with a Ct-value <30 were sequenced on the Nanopore platform. 9 Successful sequencing was defined as at least 90% of the genome covered with at least 30x coverage. The study was approved by the institutional review board under number METC2021-0309.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.06.22273503 doi: medRxiv preprint

Of the 47 patients treated, 24(51%) were male, the median age was 63 (IQR 51 - . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.06.22273503 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.06.22273503 doi: medRxiv preprint

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Quantitative analysis of mRNA-1273

COVID-19 vaccination response in immunocompromised adult hematology patients

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

SARS-CoV-2 Variants in Patients with Immunosuppression

Drivers of adaptive evolution during chronic SARS-CoV-2 infections

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands

Food and Drug Administration website